{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Boston Scientific Corp.
Boston Scientific Forms Death Cross, Signaling Potential Bearish Trend Ahead
Boston Scientific Corp. has recently encountered a Death Cross, indicating a potential shift in market sentiment. While technical indicators suggest a bearish trend, the stock has shown resilience with a one-year performance slightly outperforming the S&P 500. Mixed signals from various indicators suggest a complex market position.
Boston Scientific Corp. Experiences Evaluation Revision Amidst Market Dynamics and Performance Variability
Boston Scientific Corp. has recently revised its evaluation amid fluctuating market conditions. The stock is priced at $96.70, reflecting volatility over the past year. Performance comparisons with the S&P 500 show mixed results, with notable outperformance over three years but recent underperformance in the last month.
Is Boston Scientific Corp. technically bullish or bearish?
As of October 3, 2025, Boston Scientific Corp. is in a mildly bearish trend, indicated by bearish momentum from MACD and KST indicators, despite outperforming the S&P 500 over three years with a 144.03% return.
Is Boston Scientific Corp. technically bullish or bearish?
As of October 3, 2025, Boston Scientific Corp. shows a mildly bearish trend, with mixed signals from technical indicators and recent underperformance compared to the S&P 500, although it has outperformed the benchmark over the past three years.
Is Boston Scientific Corp. technically bullish or bearish?
As of September 10, 2025, Boston Scientific Corp. shows a mildly bullish trend, with daily moving averages indicating mild bullishness, while weekly and monthly indicators suggest a mildly bearish outlook, despite outperforming the S&P 500 over the past year.
Is Boston Scientific Corp. overvalued or undervalued?
As of July 23, 2025, Boston Scientific Corp. is considered attractive despite a high P/E ratio of 86 compared to peers, due to its strong growth potential and impressive long-term performance, having returned 135.56% over three years, significantly outpacing the S&P 500.
Is Boston Scientific Corp. technically bullish or bearish?
As of June 9, 2025, Boston Scientific Corp. shows a mildly bullish trend, supported by bullish monthly MACD and daily moving averages, though caution is advised due to a mildly bearish weekly MACD and no clear trend in Dow Theory.
Is Boston Scientific Corp. overvalued or undervalued?
As of October 1, 2024, Boston Scientific Corp. is considered very expensive and overvalued, with a P/E ratio of 86 and an EV to EBITDA of 44.86, significantly higher than its peers, despite a strong 31.72% return over the past year.
Who are in the management team of Boston Scientific Corp.?
As of March 2022, the management team of Boston Scientific Corp. includes Michael Mahoney (Chairman, President, CEO), Edward Ludwig (Lead Independent Director), and independent directors Nelda Connors, Charles Dockendorff, Yoshiaki Fujimori, and Donna James. They oversee the company's strategic direction and operations.
What does Boston Scientific Corp. do?
Boston Scientific Corporation develops and markets medical devices for various interventional specialties, with recent net sales of $4.66 billion and a net profit of $672 million. The company has a market cap of approximately $177.29 billion and key metrics include a P/E ratio of 86.00 and a dividend yield of 5,863.88%.
How big is Boston Scientific Corp.?
As of Jun 18, Boston Scientific Corp. has a market capitalization of $177.29 billion, with recent net sales of $17.55 billion and a net profit of $2.02 billion over the last four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
